Tirzepatide brings two meal-hormone effects together in one shot. What do studies establish about diabetes, weight, and continued care?

What can the main study findings tell you?

Tirzepatide combines two hormone effects in a medicine given by shot. This page follows the studies of weight, sugar, and continued care. GIP and GLP-1 are hormones carrying messages after food arrives. Together, their effects reduced hunger more than either effect alone.

SURMOUNT adults with obesity lost an average 20.9% over 72 weeks. A direct study found greater weight loss than with semaglutide. Later studies found that ongoing medicine preserved much of the loss. Stopping often let weight return despite the large earlier fall.

Each study asked a different question in a particular patient group. An average doesn't forecast what treatment will do for you. Other illnesses and side effects still matter when treatment is considered.

What did Tirzepatide do in cells, mice, and early human tests?

Tirzepatide has a 39-amino-acid chain, made from joined protein parts. The design follows GIP, a hormone released after meals. A fatty attachment holds onto protein as the medicine circulates in blood ^[7]. Removal slows, leaving roughly half the medicine after five days.

Cells grown in dishes responded to both meal-hormone effects ^[1]. Tirzepatide copied GIP more fully than GLP-1 in those cells ^[2]. These were chemical responses inside cells, rather than patients' sugar readings. Another GLP-1 test compared messages prompting insulin release with messages dulling hormone responses ^[2].

The insulin-release message was favoured over the message dulling cell responses. Researchers think that could keep the cells responding for longer. The tests didn't establish a longer GLP-1 response in treated people. Your response can't be read from cells grown in dishes.

Together, GIP and GLP-1 prompt more insulin when blood sugar rises ^[1]. Insulin helps move sugar from blood into the body's cells. The pancreas, which makes insulin, also helps you digest food. Another hormone's sugar-raising action falls while stomach emptying slows and hunger eases.

In mice, tirzepatide reduced eating and weight more than GLP-1 treatment alone ^[1]. The comparison used equal medicine amounts in those animal tests. Phase 1, the first human tests, involved 142 people ^[1]. Weekly treatment lowered weight and sugar before meals more than placebo, treatment without tirzepatide.

What did the phase 3 weight studies find in adults?

2022: What changed during SURMOUNT-1? The 72-week study followed 2,539 adults without type 2 diabetes. Doctors calculate BMI from weight and height to help judge health risks. A score of 30 marks obesity; 27 falls within overweight. People joining with overweight also needed a weight-related illness.

Chance assigned the shots, and patients didn't know their treatment. Milligrams measure the amount of medicine inside each shot. Your doctor can explain BMI alongside other health risks.

With 5 milligrams, average loss was 15.0%; with 10 milligrams, 19.5%. The 15 milligram group lost 20.9%, against 3.1% with placebo ^[4]. Placebo is a shot without the medicine under study. The 15 milligram amount exceeded earlier major weight-study losses.

During treatment, stomach trouble was the unwanted effect found most often. Most trouble was mild or moderate while medicine amounts increased. The average loss doesn't show how each patient felt.

2025: How did SURMOUNT-5 compare medicines? The 751 adults in this study had obesity, without type 2 diabetes. People knew their medicine, assigned by chance for 72 weeks. Tirzepatide amounts were 10 or 15 milligrams; semaglutide amounts were 1.7 or 2.4 milligrams.

Patients reached the largest study amount they could tolerate. At 72 weeks, average losses were 20.2% with tirzepatide and 13.7% with semaglutide ^[5]. Waists shrank more with tirzepatide as well. More patients reached losses of 10/15/20/25%, meaning each of those weight-loss goals.

2024: What happened after SURMOUNT-4 changed treatment? A 36-week period of tirzepatide first brought 20.9% average loss. Chance then assigned continued medicine or placebo for another 52 weeks. Continued medicine brought 5.5% more loss; placebo brought 14.0% regain ^[9].

Those changes were measured from weight when the groups separated. The 19.4% difference favoured continued treatment, which prevented regain and brought further loss. The paper's 95% confidence range, showing uncertainty about the amount, still supported that benefit. That range describes doubt about the amount, rather than doubt about which group did better.

At week 88, 89.5% continuing medicine had preserved at least 80% of earlier loss. Only 16.6% with placebo had preserved that much. Continued treatment helped far more patients hold onto the benefit.

2026: Could SURMOUNT-MAINTAIN keep weight off with less medicine? This 441-participant study changed treatment at week 60. One group continued its largest tolerated amount; another received 5 milligrams. A third received placebo for the following 52 weeks. At week 112, total loss was 21.9% with the largest tolerated amount ^[12].

Total loss was 16.6% with 5 milligrams and 9.9% with placebo. Each figure compares final weight with weight before the study began. Both medicine groups preserved more weight loss than the placebo group.

2024: What did SURMOUNT-CN find in China? This phase 3 study followed 210 adults at 29 centres. Nobody had diabetes, and chance assigned their weight treatment. At week 52, loss averaged 13.6% with 10 milligrams and 17.5% with 15 milligrams. The placebo group's average loss was 2.3% ^[29].

These results broadly agreed with the other large weight studies. Benefits appeared in another group of adults receiving treatment. Your own amount of weight loss still can't be predicted.

What did studies find in people with type 2 diabetes?

2021: What did SURPASS-2 find about sugar? The 40-week phase 3 study followed 1,879 adults with type 2 diabetes. These larger treatment tests compared medicines given by weekly shot. Chance assigned tirzepatide 5, 10, or 15 milligrams, or semaglutide 1 milligram.

People knew which medicine they were receiving during the study. A blood test showed average sugar across roughly three months. Tirzepatide lowered sugar more at each amount: 5, 10, and 15 milligrams ^[3]. Each tirzepatide group also lost more weight than the semaglutide group.

Stomach problems caused most unwanted effects, usually with mild or moderate severity. Better averages don't settle which medicine fits your own health. Your doctor weighs sugar benefits against trouble and other medicines.

In May 2022, approval covered adult treatment for type 2 diabetes. November 2023 approval added continuing weight care for qualifying adults. Adults with overweight needed a weight-related illness; obesity also qualified. Approval does not cover type 1 diabetes ^[6].

StatPearls is a medical handbook explaining the two meal-hormone effects ^[7]. The handbook also describes which health needs those approvals cover. Wanting lower weight alone doesn't establish a reason for approved treatment.

What changed in breathing, heart failure, and fatty liver?

SURMOUNT-OSA examined sleep apnea alongside obesity; breathing repeatedly stopped briefly during sleep. Tirzepatide patients had fewer breathing pauses for each hour asleep ^[25]. Placebo, treatment without the medicine, brought a smaller change. For adults with obesity, approval followed for sleep apnea that was moderate or severe.

SUMMIT followed people with obesity whose hearts had difficulty filling between beats ^[26]. The heart could still squeeze normally in this form of heart failure. Tirzepatide patients had fewer symptoms and could manage more exercise. Those improvements exceeded the improvements in the placebo group.

SYNERGY-NASH studied fatty liver with inflammation, meaning swelling and irritation, and scarring ^[27]. Adults had type 2 diabetes or obesity, meaning harmful excess weight. Tests of their liver tissue improved while treatment was continuing. Other liver illnesses may respond differently from the illness studied here.

2025: A review compared 56 trials involving 60,307 patients ^[30]. Some patients no longer met the tests defining sleep apnea or fatty liver illness. Improved tests don't prove that an illness has gone away permanently. Hospital stays for heart failure were also less frequent.

What remains uncertain about Tirzepatide side effects?

During medicine increases, stomach trouble was the most common complaint. People felt sick, vomited, had constipation, or passed loose stools. Your doctor also weighs the less common risks when considering treatment.

A review found more illness in the gallbladder and its drainage tubes ^[8]. The paper's 95% confidence range, showing uncertainty about the amount, still supported extra harm. The gallbladder stores fluid that helps the body digest fat. For pancreas inflammation, meaning swelling and irritation, the 95% range couldn't settle risk.

That doesn't prove that treatment cannot harm the pancreas. Cases remain a label warning, so doctors still consider pancreas illness. The Tirzepatide effects page explains thyroid warnings, lost muscle, and operation concerns.

Which daily changes appear in Tirzepatide reviews?

SURMOUNT patients often said food thoughts became less pressing during treatment. Separate interview groups put reduced appetite at 79 to 91%. These patients named feeling less hungry as a major benefit. Other interview groups put improved energy at 62 to 79%.

Different people also reported early sickness, changing stools, and sore skin. People reported research use outside treatment studies, without establishing who supplied or supervised their shots. These aren't results from a study comparing assigned treatments. A trial hasn't confirmed the changes they described.

The Tirzepatide effects page separates interviews from other personal reports. A trial's sugar findings don't confirm every person's account of feeling better. Papers behind the treatment findings appear at /references.